Moleculin Finishes Dosing for AML Clinical Trial Part
The Houston-based firm completed patient dosing for the first phase of its trial testing Annamycin for leukemia treatment.
Updated on Oct. 30, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient safety over accelerating clinical trial results?
Moleculin has successfully completed patient dosing for Part A of its MIRACLE trial, which evaluates the use of Annamycin combined with cytarabine. The study focuses on treating patients with relapsed or refractory acute myeloid leukemia.
Why it matters
Completing this phase allows the company to select the optimal dose of Annamycin for Part B of the study. The trial is a key step in evaluating potential new therapies for difficult-to-treat leukemia cases.
The Part A study population includes 90 patients, with interim data indicating an absence of cardiotoxicity in the treatment groups. The trial compares two distinct Annamycin doses against a control arm using cytarabine and a placebo.
The players
Moleculin
This is a Houston-based pharmaceutical company that focuses on the development of drug candidates for the treatment of various cancers.
The details
The randomized double-blind study measures remission rates following a single cycle of therapy for those suffering from acute myeloid leukemia. Researchers observe a 70/30 split among the first 45 subjects, though the company anticipates a final 50/50 distribution.
Timeline
October 30, 2026: Moleculin announced the completion of patient dosing.
Q1 2027: The company expects to report comprehensive Part A data.
The Big Picture
The study follows the established protocols of the MIRACLE trial, which aims to address treatment limitations for refractory leukemia patients. This milestone represents a measured progression in the company's efforts to advance therapeutic options within oncology.
The results of this study provide insights into the safety and dosing of new treatments for patients currently battling relapsed or refractory leukemia. Readers following this trial can look forward to upcoming reports that will detail the efficacy of the therapy.
The takeaway
Clinical trials serve as essential gateways for developing modern cancer therapies that offer hope for patients with limited options. Monitoring updates on these trials helps individuals and families stay informed about the evolving landscape of medical interventions.
Further reading
For additional context on current research in this field, visit our Cancer section.
More information
For more information on trial protocols, visit the clinical trial information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that pharmaceutical companies prioritize patient safety over accelerating clinical trial results?
